Skip to main content
Top
Published in: Rheumatology International 6/2013

01-06-2013 | Original Article

Atherosclerosis in male patients with ankylosing spondylitis: the relation with methylenetetrahydrofolate reductase (C677T) gene polymorphism and plasma homocysteine levels

Authors: Muharrem Geçene, Figen Tuncay, Pınar Borman, Dogan Yücel, Mehmet Senes, Behice Kaniye Yılmaz

Published in: Rheumatology International | Issue 6/2013

Login to get access

Abstract

The aim of this study was to determine the intima-media thickness (IMT) in carotid arteries and to assess the relation of these values with plasma homocysteine (pHcy) levels and methylenetetrahydrofolate reductase (MTHFR) C677T gene polymorphism in patients with Ankylosing spondylitis (AS). Serum lipids, vitamin B12, folic acid, pHcy and acute phase protein levels were measured in all cases. MTHFR C677T gene polymorphisms were determined, and IMT of main carotid artery were evaluated ultrasonographically in all subjects. Bath Ankylosing Spondylitis Disease Activity Index, Ankylosing Spondylitis Disease Activity score and Bath Ankylosing Spondylitis Metrology Index were used to assess disease activity and spinal mobility. Fifty AS patients (mean age of 36.6 ± 4.79 years) and 50 control subjects (36.34 ± 4.72 years) were included in the study. Plasma homocysteine levels of AS patients and control group were also similar (14.26 ± 9.96 vs. 11.81 ± 5.53 μmol/L). Hyperhomocysteinemia was present in 11 subjects in patient group (22.0 %), while it was seen in 5 subjects in the control group (10.0 %). The MTHFR C677T genotype distribution was as follows: CC 31 (62 %), CT 14 (28 %), TT 5 (10 %) in AS patients. The mean carotid IMT values were also found to be similar between the groups. The most important factor influencing pHcy level was found as MTHFR 677TT genotype. We indicated no difference of atherosclerosis indices revealed by IMT values and pHcy levels AS patients and control subjects. But an association between MTHFR 677 gene polymorphism and pHcy levels was concluded, which may suggest that MTHFR 677 TT polymorphism may be a potential prognostic factor for cardiovascular disease in patients with AS.
Literature
1.
go back to reference Choe JY, Lee MY, Rheem I, Rhee MY, Park SH, Kim SK (2008) No differences of carotid intima-media thickness between young patients with ankylosing spondylitis and healthy controls. Joint Bone Spine 75:548–553CrossRefPubMed Choe JY, Lee MY, Rheem I, Rhee MY, Park SH, Kim SK (2008) No differences of carotid intima-media thickness between young patients with ankylosing spondylitis and healthy controls. Joint Bone Spine 75:548–553CrossRefPubMed
2.
go back to reference Palazzi C, D’Angelo S, Lubrano E, Olivieri I (2008) Aortic involvement in ankylosing spondylitis. Clin Exp Rheumatol 26:131–134 Palazzi C, D’Angelo S, Lubrano E, Olivieri I (2008) Aortic involvement in ankylosing spondylitis. Clin Exp Rheumatol 26:131–134
3.
go back to reference Mathieu S, Joly H, Baron G, Tournadre A, Dubost JJ, Ristori JM, Lusson JR, Soubrier M (2008) Trend towards increased arterial stiffness or intima-media thickness in ankylosing spondylitis patients without clinically evident cardiovascular disease. Rheumatology 47:1203–1207CrossRefPubMed Mathieu S, Joly H, Baron G, Tournadre A, Dubost JJ, Ristori JM, Lusson JR, Soubrier M (2008) Trend towards increased arterial stiffness or intima-media thickness in ankylosing spondylitis patients without clinically evident cardiovascular disease. Rheumatology 47:1203–1207CrossRefPubMed
4.
go back to reference Heeneman S, Daemen MJ (2007) Cardiovascular risks in spondyloarthritis. Curr Opin Rheumatol 19:358–362CrossRefPubMed Heeneman S, Daemen MJ (2007) Cardiovascular risks in spondyloarthritis. Curr Opin Rheumatol 19:358–362CrossRefPubMed
5.
go back to reference Han C, Robinson DW Jr, Hackett MV, Paramore LC, Fraeman KH, Bala MV (2006) Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 33:2167–2172PubMed Han C, Robinson DW Jr, Hackett MV, Paramore LC, Fraeman KH, Bala MV (2006) Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 33:2167–2172PubMed
6.
go back to reference Wei JC, Jan MS, Yu CT, Huang YC, Yang CC, Tsou HK, Lee HS, Chou CT, Tsay G, Chou MC (2007) Plasma homocysteine status in patients with ankylosing spondylitis. Clin Rheumatol 739–42CrossRefPubMed Wei JC, Jan MS, Yu CT, Huang YC, Yang CC, Tsou HK, Lee HS, Chou CT, Tsay G, Chou MC (2007) Plasma homocysteine status in patients with ankylosing spondylitis. Clin Rheumatol 739–42CrossRefPubMed
7.
go back to reference Başkan BM, Sivas F, Aktekin LA, Doğan YP, Ozoran K, Bodur H (2009) Serum homocysteine level in patients with ankylosing spondylitis. Rheumatol Int 29:1435–1439CrossRefPubMed Başkan BM, Sivas F, Aktekin LA, Doğan YP, Ozoran K, Bodur H (2009) Serum homocysteine level in patients with ankylosing spondylitis. Rheumatol Int 29:1435–1439CrossRefPubMed
8.
go back to reference Khandanpour N, Willis G, Meyer FJ, Armon MP, Loke YK, Wright AJ, Finglas PM, Jennings BA (2009) Peripheral arterial disease and methylenetetrahydrofolate reductase (MTHFR) C677T mutations: a case-control study and meta-analysis. J Vasc Surg 49:711–718CrossRefPubMed Khandanpour N, Willis G, Meyer FJ, Armon MP, Loke YK, Wright AJ, Finglas PM, Jennings BA (2009) Peripheral arterial disease and methylenetetrahydrofolate reductase (MTHFR) C677T mutations: a case-control study and meta-analysis. J Vasc Surg 49:711–718CrossRefPubMed
9.
go back to reference Cho SE, Hong KS, Shin GJ, Chung WS (2006) The methylenetetrahydrofolate reductase C677T gene mutation is associated with hyperhomocysteinemia, cardiovascular disease and plasma B-type natriuretic peptide levels in Korea. Clin Chem Lab Med 44:1070–1075CrossRefPubMed Cho SE, Hong KS, Shin GJ, Chung WS (2006) The methylenetetrahydrofolate reductase C677T gene mutation is associated with hyperhomocysteinemia, cardiovascular disease and plasma B-type natriuretic peptide levels in Korea. Clin Chem Lab Med 44:1070–1075CrossRefPubMed
10.
go back to reference van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthr Rheum 27:361–368CrossRef van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthr Rheum 27:361–368CrossRef
11.
go back to reference Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21:2286–2291PubMed Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21:2286–2291PubMed
12.
go back to reference Machado P, Landewe R, Lie E et al (2011) Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis 70:47–53CrossRefPubMed Machado P, Landewe R, Lie E et al (2011) Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis 70:47–53CrossRefPubMed
13.
go back to reference Jenkinson TR, Mallorie PA, Whitelock HC et al (1994) Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. J Rheumatol 21:1694–1698PubMed Jenkinson TR, Mallorie PA, Whitelock HC et al (1994) Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. J Rheumatol 21:1694–1698PubMed
14.
go back to reference Kumeda Y, Inaba M, Goto H, Nagata M, Henmi Y, Furumitsu Y, Ishimura E, Inui K, Yutani Y, Miki T, Shoji T, Nishizawa Y (2002) Increased thickness of the arterial intima-media detected by ultrasonography in patients with rheumatoid arthritis. Arthr Rheum 46:1489–1497CrossRef Kumeda Y, Inaba M, Goto H, Nagata M, Henmi Y, Furumitsu Y, Ishimura E, Inui K, Yutani Y, Miki T, Shoji T, Nishizawa Y (2002) Increased thickness of the arterial intima-media detected by ultrasonography in patients with rheumatoid arthritis. Arthr Rheum 46:1489–1497CrossRef
15.
go back to reference Chambless LE, Heiss G, Folsom AR, Rosamond W, Szklo M, Sharrett AR, Clegg LX (1997) Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987–1993. Am J Epidemiol 146:483–494CrossRefPubMed Chambless LE, Heiss G, Folsom AR, Rosamond W, Szklo M, Sharrett AR, Clegg LX (1997) Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987–1993. Am J Epidemiol 146:483–494CrossRefPubMed
16.
go back to reference O’Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr (1999) Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 340:14–22CrossRefPubMed O’Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr (1999) Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 340:14–22CrossRefPubMed
17.
go back to reference van der Meer IM, Bots ML, Hofman A, del Sol AI, van der Kuip DA, Witteman JC (2004) Predictive value of noninvasive measures of atherosclerosis for incident myocardial infarction: the Rotterdam Study. Circulation 109:1089–1094CrossRefPubMed van der Meer IM, Bots ML, Hofman A, del Sol AI, van der Kuip DA, Witteman JC (2004) Predictive value of noninvasive measures of atherosclerosis for incident myocardial infarction: the Rotterdam Study. Circulation 109:1089–1094CrossRefPubMed
18.
go back to reference Erre GL, Sanna P, Zinellu A, Ponchietti A, Fenu P, Sotgia S, Carru C, Ganau A, Passiu G (2011) Plasma asymmetric dimethylarginine (ADMA) levels and atherosclerotic disease in ankylosing spondylitis: a cross-sectional study. Clin Rheumatol 30:21–27CrossRefPubMed Erre GL, Sanna P, Zinellu A, Ponchietti A, Fenu P, Sotgia S, Carru C, Ganau A, Passiu G (2011) Plasma asymmetric dimethylarginine (ADMA) levels and atherosclerotic disease in ankylosing spondylitis: a cross-sectional study. Clin Rheumatol 30:21–27CrossRefPubMed
19.
go back to reference Peters MJ, van Eijk IC, Smulders YM, Serne E, Dijkmans BA, van der Horst-Bruinsma IE, Nurmohamed MT (2010) Signs of accelerated preclinical atherosclerosis in patients with ankylosing spondylitis. J Rheumatol 37:161–166CrossRefPubMed Peters MJ, van Eijk IC, Smulders YM, Serne E, Dijkmans BA, van der Horst-Bruinsma IE, Nurmohamed MT (2010) Signs of accelerated preclinical atherosclerosis in patients with ankylosing spondylitis. J Rheumatol 37:161–166CrossRefPubMed
20.
go back to reference Malesci D, Niglio A, Mennillo GA, Buono R, Valentini G, La Montagna G (2007) High prevalence of metabolic syndrome in patients with ankylosing spondylitis. Clin Rheumatol 26:710–714CrossRefPubMed Malesci D, Niglio A, Mennillo GA, Buono R, Valentini G, La Montagna G (2007) High prevalence of metabolic syndrome in patients with ankylosing spondylitis. Clin Rheumatol 26:710–714CrossRefPubMed
21.
go back to reference Taraborelli M, Andreoli L, Archetti S, Ferrari M, Cattaneo R, Tincani A (2009) Methylenetetrahydrofolate reductase polymorphisms and methotrexate: no association with response to therapy nor with drug-related adverse events in an Italian population of rheumatic patients. Clin Exp Rheumatol 27:499–502PubMed Taraborelli M, Andreoli L, Archetti S, Ferrari M, Cattaneo R, Tincani A (2009) Methylenetetrahydrofolate reductase polymorphisms and methotrexate: no association with response to therapy nor with drug-related adverse events in an Italian population of rheumatic patients. Clin Exp Rheumatol 27:499–502PubMed
22.
go back to reference Tasbas O, Borman P, Gürhan Karabulut H, Tükün A, Yorgancıoğlu R (2011) The frequency of A1298C and C677T polymorphisms of the methylenetetrahydrofolate gene in Turkish patients with rheumatoid arthritis: relationship with methotrexate toxicity. Open Rheumatol J 5:30–35CrossRefPubMedPubMedCentral Tasbas O, Borman P, Gürhan Karabulut H, Tükün A, Yorgancıoğlu R (2011) The frequency of A1298C and C677T polymorphisms of the methylenetetrahydrofolate gene in Turkish patients with rheumatoid arthritis: relationship with methotrexate toxicity. Open Rheumatol J 5:30–35CrossRefPubMedPubMedCentral
23.
go back to reference van Ede AE, Laan RF, Blom HJ, Huizinga TW, Haagsma CJ, Giesendorf BA, de Boo TM, van de Putte LB (2001) The C677T mutation in the methylenetetrahydrofolate reductase gene: a genetic risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patients. Arthritis Rheum 44:2525–2530CrossRefPubMed van Ede AE, Laan RF, Blom HJ, Huizinga TW, Haagsma CJ, Giesendorf BA, de Boo TM, van de Putte LB (2001) The C677T mutation in the methylenetetrahydrofolate reductase gene: a genetic risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patients. Arthritis Rheum 44:2525–2530CrossRefPubMed
24.
go back to reference Gonzalez-Lopez L, Sanchez-Hernandez JD, Aguilar-Chavez EA, Cota-Sanchez AR, Lopez-Olivo MA, Villa-Manzano AI, Ortega-Flores R, Espinoza-Magaña GL, Rojo-Contreras W, Cardona-Muñoz EG, Gamez-Nava JI (2008) Hyperhomocysteinemia in ankylosing spondylitis: prevalence and association with clinical variables. Rheumatol Int 28:1223–1228CrossRefPubMed Gonzalez-Lopez L, Sanchez-Hernandez JD, Aguilar-Chavez EA, Cota-Sanchez AR, Lopez-Olivo MA, Villa-Manzano AI, Ortega-Flores R, Espinoza-Magaña GL, Rojo-Contreras W, Cardona-Muñoz EG, Gamez-Nava JI (2008) Hyperhomocysteinemia in ankylosing spondylitis: prevalence and association with clinical variables. Rheumatol Int 28:1223–1228CrossRefPubMed
25.
go back to reference Ghilardi G (1994) Carotid stenotic-obliterative lesions. Distribution in 16,379 subjects 45–75 years of age. Minerva Cardioangiol 42:345–350PubMed Ghilardi G (1994) Carotid stenotic-obliterative lesions. Distribution in 16,379 subjects 45–75 years of age. Minerva Cardioangiol 42:345–350PubMed
Metadata
Title
Atherosclerosis in male patients with ankylosing spondylitis: the relation with methylenetetrahydrofolate reductase (C677T) gene polymorphism and plasma homocysteine levels
Authors
Muharrem Geçene
Figen Tuncay
Pınar Borman
Dogan Yücel
Mehmet Senes
Behice Kaniye Yılmaz
Publication date
01-06-2013
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 6/2013
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-012-2552-8

Other articles of this Issue 6/2013

Rheumatology International 6/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine